JPMorgan Chase & Co. set a $85.00 target price on Eli Lilly and Co. (NYSE:LLY) in a research note released on Thursday morning. The firm currently has a buy rating on the stock.
A number of other analysts also recently weighed in on the company. Goldman Sachs Group Inc. upgraded Eli Lilly and from a neutral rating to a buy rating and boosted their target price for the stock from $89.00 to $95.00 in a research report on Tuesday, September 27th. Zacks Investment Research downgraded Eli Lilly and from a buy rating to a hold rating in a research report on Thursday, August 4th. Jefferies Group restated a buy rating and issued a $105.00 target price on shares of Eli Lilly and in a research report on Wednesday, September 14th. Argus boosted their target price on Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a research report on Tuesday, August 2nd. Finally, Leerink Swann restated a buy rating and issued a $103.00 target price on shares of Eli Lilly and in a research report on Sunday, October 9th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $92.34.
Eli Lilly and (NYSE:LLY) traded up 1.65% during trading on Thursday, hitting $69.12. The company’s stock had a trading volume of 8,620,682 shares. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $88.16. The firm has a 50 day moving average of $76.69 and a 200 day moving average of $77.92. The firm has a market cap of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 EPS. Equities research analysts predict that Eli Lilly and will post $3.55 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. The ex-dividend date is Thursday, November 10th. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio (DPR) is presently 88.70%.
In other news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of LLY. Iowa State Bank acquired a new position in Eli Lilly and during the second quarter valued at about $104,000. PineBridge Investments L.P. raised its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock valued at $108,000 after buying an additional 920 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in Eli Lilly and by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares in the last quarter. Integrated Wealth Management raised its stake in Eli Lilly and by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock valued at $112,000 after buying an additional 50 shares in the last quarter. Finally, Financial Architects Inc raised its stake in Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock valued at $114,000 after buying an additional 61 shares in the last quarter. 75.11% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile